9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 32

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Best Overall Response by RECIST Criteria (Version 1.0),  Overall Survival,  Progression-Free Survival,

Interventions: pemetrexed disodium, gemcitabine hydrochloride

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: September 2009

Completion Date: May 2011

Last  Posted Date: December 4, 2012

Location: Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States

Website Link: https://ClinicalTrials.gov/show/NCT00101283

Was this article helpful?
Dislike 0